More MS news articles for Feb 2002

T cell vaccination in multiple sclerosis: results of a preliminary study

Journal of Neurology
Abstract Volume 249 Issue 2 (2002) pp 212-218
Jingwu Z. Zhang (1)(3), Victor M. Rivera (3), Maria V. Tejada-Simon (3), Deye Yang (3), Jian Hong (3), Sufanfg Li (3), Hani Haykal (2), James Killian (3), Ying C. Q. Zang (3)
(1) Department of Immunology, Baylor College of Medicine
(2) Department of Radiology, The Methodist Hospital, Houston, USA.
(3) Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA, Tel.: +1-7 13/7 98-37 90, Fax: +1-7 13/7 98-56 65

Abstract Myelin basic protein (MBP)-reactive T cells are potentially involved in the pathogenesis of multiple sclerosis (MS), and can be depleted by subcutaneous inoculations with irradiated autologous MBP-reactive T cells (T cell vaccination).

This preliminary open label study was undertaken to evaluate whether depletion of MBP-reactive T cells would be clinically beneficial to patients with MS.

Fifty-four patients with relapsing-remitting (RR) MS (n=28) or secondary progressive (SP) MS (n=26) were immunized with irradiated autologous MBP-reactive T cells and monitored for changes in rate of relapse, expanded disability scale score (EDSS) and MRI lesion activity over a period of 24 months.

Depletion of MBP-reactive T cells correlated with a reduction (40 %) in rate of relapse in RR-MS patients as compared with the pre-treatment rate in the same cohort.

However, the reduction in EDSS was minimal in RR-MS patients while the EDSS was slightly increased in SP-MS patients over a period of 24 months.

Serial semi-quantitative MRI examinations suggest stabilization in lesion activity as compared with baseline MRI.

The findings suggest some potential clinical benefit of T cell vaccination in MS and encourage further investigations to evaluate the treatment efficacy of T cell vaccination in controlled trials.

© Steinkopff Verlag 2002